Ascend Gmbh Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Ascend Gmbh Pharmaceutical Import Records from India — 2 Products, $3.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ascend Gmbh — Pharmaceutical Importer Profile (2026) | 2 Products, $3.8M Trade | TransData Nexus

Ascend Gmbh

Pharmaceutical Importer · Germany · Immunosuppressants Focus · $3.8M Total Trade · DGFT Verified

Ascend Gmbh is a pharmaceutical importer based in Germany with a total trade value of $3.8M across 2 products in 1 therapeutic categories. Based on 75 verified import shipments from Indian Customs (DGFT) records, Ascend Gmbh is the #1 buyer in 1 product including Everolimus. Ascend Gmbh sources from 1 verified Indian supplier, with Alkem Laboratories Limited accounting for 100.0% of imports.

Ascend Gmbh — Import Portfolio & Supplier Network

Ascend Gmbh import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ascend Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Alkem Laboratories Limited	$7.3M	495	100.0%

Ascend Gmbh sources from 1 verified Indian supplier across 376 distinct formulations. The sourcing is highly concentrated — Alkem Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Ascend Gmbh Import?

Formulation	Value	Ships
Ezetimibe tablets 10 MG 10x10 s de pzn	$250.0K	5
Mycophenolate ascend TAB 500MG 25x10s de pzn no16127381each flim coated tablet contains:mycophenolate	$150.0K	3
Mycophenolate ascend tablets 500MG (mycophenolate mofetil tablets 500MG) [11739pack x 15x10's] batch no. 24120518	$150.0K	3
Solifenacin alkem 10 MG TAB 9x10'sde pzn no15611494each flim coatedtablet contains:solifenacin succinate	$148.0K	3
Mycophenolate ascend tablets 500MG (mycophenolate mofetil tablets 500MG) [7864 Pack x 15x10's] batch no. 23123994 &	$128.6K	3
Eslicarbazepin ascend 800 MG TAB 9x10	$100.0K	2
Mycophenolate ascend TAB 500 MG 25x10s	$100.0K	2
Ezetimibe tablets 10MG Each film TAB cont. ezetimibe 10MG [18783 Pack x 10x10's] batch no. 23122388 manufacturing dt. 08/23	$100.0K	2
Mycophenolate ascend tablets 500MG eachflim coated tablet contains: mycophenolate mofetil 500MG [4725 x 25x10's]	$100.0K	2
Pharmaceutical products mycophenolate ascend TAB 500MG 25x10s de pznno	$100.0K	2
Pharmaceutical products pregabalinascend capsule100mg 10x10s	$100.0K	2
Pharmaceutical products pregabalinascend capsule 75MG 10x10s de	$100.0K	2
Pharmaceutical article / ods / product / item mycophenolate	$92.1K	4
Solifenacin alkem 5 MG TAB 9x10's de pzn no15611465each flim coated tablet contains:solifenacin succinate 5MG	$83.5K	3
Pharmaceutical products:mycophenolate ascend TAB 500MG 15x10s de pzn no16127375each flim coated tablet	$78.9K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Mycophenolate	Immunosuppressants	$2.4M	48	0.7%	13
2	Everolimus	Immunosuppressants	$1.4M	27	3.6%	1

Ascend Gmbh imports 2 pharmaceutical products across 1 categories into Germany totaling $3.8M. The company is the #1 buyer for 1 product: Everolimus.

Ascend Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ascend GmbH is a German pharmaceutical company specializing in the import and distribution of high-quality generic medicines. Established in 2009, Ascend has rapidly developed into a significant player in the German pharmaceutical market, supplying a wide range of prescription medications to pharmacies and hospitals nationwide. The company's mission is to provide patients with timely access to affordable generics without compromising on safety or quality. (ascend-de.eu)

In 2019, Ascend GmbH became a 100% subsidiary of Alkem Laboratories Limited, a global pharmaceutical company headquartered in India. This strategic partnership leverages Alkem's extensive research and development capabilities, enabling Ascend to offer a diverse portfolio of generics across various therapeutic areas. The collaboration underscores Ascend's commitment to sustainable and equitable healthcare, aiming to provide all patients in Germany with rapid access to affordable generics. (ascend-de.eu)

2Distribution Network

Ascend GmbH operates a robust distribution network to ensure efficient delivery of pharmaceutical products across Germany. The company's logistics infrastructure includes strategically located warehouses and partnerships with third-party logistics providers, facilitating nationwide coverage. While specific warehouse locations are not publicly disclosed, Ascend's operations are designed to meet the demands of the German market effectively. The company emphasizes environmental responsibility in its logistics operations, aligning with its commitment to sustainability. (ascend-de.eu)

3Industry Role

In Germany's pharmaceutical supply chain, Ascend GmbH functions primarily as a wholesaler and distributor of generic medicines. The company imports finished pharmaceutical formulations from its parent company, Alkem Laboratories Limited, and other suppliers, ensuring a steady supply of affordable generics to the German market. Ascend's role is pivotal in bridging the gap between manufacturers and healthcare providers, facilitating access to essential medications for patients across the country. (ascend-de.eu)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ascend Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ascend GmbH's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, Alkem Laboratories Limited. This concentrated sourcing approach can offer benefits such as streamlined logistics, consistent product quality, and favorable pricing agreements. However, it also introduces potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges within the supplier's facilities. The stability of this relationship is crucial for Ascend's operations, and any disturbances could impact the availability of products in the German market. (ascend-de.eu)

2Supply Chain Resilience

The resilience of Ascend GmbH's supply chain is closely tied to the operational stability of Alkem Laboratories Limited. While Ascend imports a diverse range of formulations, the heavy reliance on a single supplier may limit the company's ability to quickly adapt to supply chain disruptions. To enhance resilience, Ascend could consider diversifying its supplier base and establishing relationships with additional manufacturers. Additionally, evaluating alternative shipping routes and ensuring compliance with international regulatory standards can further strengthen the supply chain's robustness. Proactive risk management strategies are essential to mitigate potential disruptions and maintain a consistent supply of pharmaceuticals to the German market. (ascend-de.eu)

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the primary regulatory authority overseeing the approval and distribution of pharmaceutical products. The German Medicines Act (AMG) provides the legal framework governing the manufacturing, approval, dispensing, and importation of medicines. For Indian generics to be marketed in Germany, they must obtain a national marketing authorization from BfArM, ensuring compliance with stringent safety, efficacy, and quality standards. This process involves submitting comprehensive documentation to demonstrate the product's bioequivalence to the reference medicine. (pspharmaservice.de)

2Import Licensing & GMP

Importing pharmaceutical products into Germany requires adherence to specific licensing and Good Manufacturing Practice (GMP) standards. Importers must obtain an import permit in accordance with Section 72 of the German Medicines Act (AMG), which mandates compliance with personnel and material requirements similar to those for manufacturing medicinal products. Additionally, imported medicines must be manufactured in facilities that adhere to recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. This ensures that the products meet the necessary quality standards for distribution within Germany.

Ascend Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ascend GmbH's product strategy focuses on importing generics in therapeutic areas with high demand and limited competition. The company's portfolio includes medications such as Everolimus and Mycophenolate, which are essential in the treatment of conditions like organ transplant rejection and certain cancers. The decision to import these specific products is driven by market needs and the opportunity to provide cost-effective alternatives to patients. By focusing on these therapeutic areas, Ascend aims to address critical healthcare needs while maintaining a competitive edge in the German market. (ascend-de.eu)

2Sourcing Profile

Ascend GmbH's sourcing strategy emphasizes the importation of generic drugs from India, leveraging the country's robust pharmaceutical manufacturing capabilities. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. This approach ensures that the products are ready for distribution upon arrival, streamlining the supply chain and reducing time to market. India's adherence to international GMP standards and its cost-effective manufacturing processes make it a strategic partner for Ascend's procurement needs. (ascend-de.eu)

3Market Positioning

Seller's Guide — How to Become a Supplier to Ascend Gmbh

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to collaborate with Ascend GmbH, especially in therapeutic areas where Ascend's current sourcing may be limited. By offering high-quality generics that meet German regulatory standards, Indian exporters can fill gaps in Ascend's product portfolio, enhancing the company's competitiveness and supply chain resilience. Establishing partnerships with Ascend could lead to increased market access and a stronger presence in the German pharmaceutical sector. (ascend-de.eu)

2Requirements & Qualifications

Indian exporters aiming to supply Ascend GmbH and the German market must ensure that their products comply with EU GMP standards and obtain the necessary marketing authorizations from the Federal Institute for Drugs and Medical Devices (BfArM). Products must undergo batch testing and stability studies to meet German quality standards. Labeling must be in the German language, providing comprehensive product information. Additionally, adherence to serialization requirements is mandatory to prevent counterfeit medicines. Meeting these standards is essential for successful market entry and distribution in Germany.

TransData Nexus Research · Industry procurement practices

Frequently Asked Questions — Ascend Gmbh

What products does Ascend Gmbh import from India?

Ascend Gmbh imports 2 pharmaceutical products across 1 categories. Top imports: Mycophenolate ($2.4M), Everolimus ($1.4M).

Who supplies pharmaceuticals to Ascend Gmbh from India?

Ascend Gmbh sources from 1 verified Indian suppliers. The primary supplier is Alkem Laboratories Limited (100.0% of imports, $7.3M).

What is Ascend Gmbh's total pharmaceutical import value?

Ascend Gmbh's total pharmaceutical import value from India is $3.8M, based on 75 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ascend Gmbh focus on?

Ascend Gmbh imports across 1 categories. The largest: Immunosuppressants (100.0%).

Get Full Ascend Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.